Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL2111842 | 0.98 | FDPS (0.36) | FDPSCYP19A1 | |
| Water SCHEMBL921702 | 0.80 | FDPS (0.38) | FDPSCYP19A1 | |
| SCHEMBL240573 | 0.77 | FDPS (0.43) | FDPSCYP19A1 | |
| Water SCHEMBL2111846 | 0.76 | FDPS (0.42) | FDPSCYP19A1 | |
| SCHEMBL7245729 | 0.68 | FDPS (0.44) | FDPSCYP19A1 | |
| SCHEMBL2949292 | 0.67 | FDPS (0.47) | FDPSCYP19A1 | |
| SCHEMBL28888016 | 0.67 | FDPS (0.43) | FDPSCYP19A1 | |
| SCHEMBL29263780 | 0.67 | KMT2A (0.41) | CYP19A1 | |
| Phosphoric Acid SCHEMBL28121884 | 0.64 | FDPS (0.43) | FDPSCYP19A1 | |
| SCHEMBL21327739 | 0.64 | FDPS (0.43) | FDPSCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013817-B2 | Nanoparticles for drug delivery to treat bone disease | THE CLEVELAND CLINIC FOUNDATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200121703-A1 | CANCER TREATMENT | THE CLEVELAND CLINIC FOUNDATION | 2020-04-23 | — | — | US | disclosed |
| US-20190307896-A1 | NANOPARTICLES FOR DRUG DELIVERY TO TREAT BONE DISEASE | THE CLEVELAND CLINIC FOUNDATION | 2019-10-10 | — | — | US | disclosed |
| EP-3125884-A2 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | The Regents of the University of Michigan (US) | 2017-02-08 | — | — | EP | disclosed |
| WO-2015153959-A2 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-10-08 | — | — | WO | disclosed |
| US-8518914-B2 | HMG-CoA reductase and farnesyl-pyrophosphate synthase inhibitors for the treatment of conditions related to prenylated proteins in cells | UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II (FR) | 2013-08-27 | — | — | US | disclosed |
| EP-1286665-B1 | TREATMENT REGIMEN OF INTRAVENOUS ZOLEDRONATE FOR THE TREATMENT OF BONE METABOLISM DISEASES | NOVARTIS AG (CH) | 2013-04-17 | — | — | EP | disclosed |
| WO-2013052943-A2 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHGIAN (US) | 2013-04-11 | — | — | WO | disclosed |
| EP-2192126-B1 | Process for making zoledronic acid | SYNTHON BV (NL) | 2013-03-27 | — | — | EP | disclosed |
| US-8324189-B2 | Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2012-12-04 | — | — | US | disclosed |
| US-20070021617-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20070021616-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20070021619-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20070021618-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20070021389-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | ARONHIME JUDITH | 2007-01-25 | — | — | US | disclosed |
| US-20060178439-A1 | Crystalline form of zoledronic acid | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-08-10 | — | — | US | disclosed |
| EP-1612212-A1 | Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation | Teva Pharmaceutical Industries Ltd (IL) | 2006-01-04 | — | — | EP | disclosed |
| US-20040014724-A1 | Method of administering a bisphosphonate | SEAMAN JOHN J (US) | 2004-01-22 | — | — | US | disclosed |
| EP-1286665-A2 | USE OF ZOLENDRONATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BONE METABOLISM DISEASES | Novartis AG (CH) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001089494-A2 | USE OF ZOLENDRONATE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BONE METABOLISM DISEASES | NOVARTIS AG (CH) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178439-A1 | Crystalline form of zoledronic acid | FGF23, PTH1R, SOST | FDPS 1039/4885CYP19A1 820/4885 |
| US-20040014724-A1 | Method of administering a bisphosphonate | PTH1R, PPIP5K2, BPGM | FDPS 718/4885CYP19A1 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.